Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.

Journal of translational medicine - 11 Apr 2018

Cavallari Larisa H, Franchi Francesco, Rollini Fabiana, Been Latonya, Rivas Andrea, Agarwal Malhar, Smith D Max, Newsom Kimberly, Gong Yan, Elsey Amanda R, Starostik Petr, Johnson Julie A, Angiolillo Dominick J

Abstract excerpt

BACKGROUND: The CYP2C19 nonfunctional genotype reduces clopidogrel effectiveness after percutaneous coronary intervention (PCI). Following clinical implementation of CYP2C19 genotyping at University Florida (UF) Health Shands Hospital in 2012, where genotype results are available approximately 3 days after PCI, testing was expanded to UF Health Jacksonville in 2016 utilizing a rapid genotyping approach. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiplatelet Therapy and Cardiovascular Diseases
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Genotyping Techniques

Share to Mechanical Circulatory Support Devices

Share to Percutaneous Coronary Intervention

Share to Phenotype

Share to Platelet Aggregation Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 29642909
DOI: 10.1186/s12967-018-1469-8
PMCID: PMC5896099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.PMID 29642909Read ↗

Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory.Semantic proximity Read ↗

Point of care CYP2C19 genotyping after percutaneous coronary intervention.Semantic proximity Read ↗

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary InterventionSemantic proximity Read ↗

Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial.Semantic proximity Read ↗

Clinical impact of preemptive pharmacogenomic testing on antiplatelet therapy in a real-world setting.Semantic proximity Read ↗

Comparison of Two Point-of-Care CYP2C19 Genotyping Assays for Genotype-Guided Antiplatelet Therapy.Semantic proximity Read ↗

CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.Semantic proximity Read ↗

Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.Semantic proximity Read ↗

Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program.Semantic proximity Read ↗

Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.Semantic proximity Read ↗

The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.